Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)
PHILADELPHIA and OXFORD, United Kingdom, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announced that it will present three posters at the 2016 SITC annual meeting. The posters summarize: (1) preclinical data from Adaptimmune’s wholly-owned MAGE-A4 SPEAR™ (Specific Peptide Enhanced Affinity Receptor) T‑cell therapy, (2) preclinical data from the Company’s second generation SPEAR T-cell engineered to overcome immunosuppression in the tumor microenvironment, and (3) a single-patient case study from the Company’s ongoing synovial sarcoma study. The 2016 SITC annual meeting will take place at the Gaylord National Hotel & Convention Center in National Harbor, Maryland on November 9 through 13, 2016.
Details regarding the three presentations are as follows:
Friday, November 11, 2016
Poster Presentation
Poster number: 3
Title: “Preclinical evaluation of an optimal-affinity MAGE-A4 T cell receptor for adoptive T cell therapy”
Presentation Time: 12:15 – 1:30pm
Location: Prince George's Exhibition Hall AB
This presentation will summarize the preclinical profile for our wholly-owned SPEAR T-cell therapy targeting the MAGE-A4 cancer-germline antigen.
Friday, November 11, 2016
Poster Presentation
Poster number: 5
Title: “Engineering 2nd Generation SPEAR T-cells to overcome FACTOR-mediated immunosuppression for adoptive cell therapy”
Presentation Time: 12:15 – 1:30pm
Location: Prince George's Exhibition Hall AB
This presentation will summarize preclinical data from Adaptimmune’s first, 2nd generation SPEAR T-cell designed to overcome tumor immunosuppression by expressing an additional factor (which will be announced the day of the presentation).
Saturday, November 12, 2016
Poster Presentation
Poster number: 4
Title: “Case Report: Specific Peptide Enhanced Affinity Receptor T-cells (SPEAR T-cells) demonstrate long-term persistence and both in vivo and ex vivo tumoricidal activity”
Presentation Time: 11:45 – 1:00pm
Location: Prince George's Exhibition Hall AB
Data presented will be from a single-patient case study from the ongoing synovial sarcoma trial. SPEAR T-cells were profiled and phenotyped during this patient’s treatment.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR™ (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the Company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance targeted for 2017. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 8, 2016, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts Investor Relations Will Roberts T: (215) 825-9306 E: will.roberts@adaptimmune.com Juli P. Miller, Ph.D. T: (215) 825-9310 E: juli.miller@adaptimmune.com Media Relations Margaret Henry T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com
Released November 8, 2016